CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Eli Lilly CEO Dave Ricks made $114 million in 2024, according to a new proxy statement to investors, putting him in the rare company of health care executives who have pulled in at least nine ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health executive pulling in nine figures in a single year. Lilly also disclosed about ...

Eli Lilly is offering vials of its obesity drug Zepbound to patients at a discount — but only if they skip their insurance.

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the ...

Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial ...